{"id":411814,"date":"2025-11-23T13:30:00","date_gmt":"2025-11-23T12:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=411814"},"modified":"2025-11-23T17:20:11","modified_gmt":"2025-11-23T16:20:11","slug":"de-nouvelles-options-therapeutiques-pour-les-patients-atteints-de-myelofibrose-a-haut-risque-danemie","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/de-nouvelles-options-therapeutiques-pour-les-patients-atteints-de-myelofibrose-a-haut-risque-danemie\/","title":{"rendered":"De nouvelles options th\u00e9rapeutiques pour les patients atteints de my\u00e9lofibrose \u00e0 haut risque d’an\u00e9mie ?"},"content":{"rendered":"\n

La my\u00e9lofibrose est consid\u00e9r\u00e9e comme l’une des n\u00e9oplasies my\u00e9loprolif\u00e9ratives les plus complexes – avec une charge symptomatique \u00e9lev\u00e9e, une cytop\u00e9nie progressive et des options th\u00e9rapeutiques limit\u00e9es – et l’an\u00e9mie, en particulier, constitue un d\u00e9fi clinique qui s’aggrave souvent sous inhibition JAK conventionnelle. Une \u00e9tude multicentrique publi\u00e9e en ao\u00fbt 2025 par une \u00e9quipe de chercheurs italiens fournit d\u00e9sormais des preuves proches des soins pour le momelotinib en tant qu’option potentiellement modificatrice de la maladie pour restaurer l’\u00e9rythropo\u00ef\u00e8se et contr\u00f4ler les sympt\u00f4mes li\u00e9s \u00e0 la rate. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

La my\u00e9lofibrose est consid\u00e9r\u00e9e comme l’une des n\u00e9oplasies my\u00e9loprolif\u00e9ratives les plus complexes – avec une charge symptomatique \u00e9lev\u00e9e, une cytop\u00e9nie progressive et des options th\u00e9rapeutiques limit\u00e9es – et l’an\u00e9mie, en……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":411817,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"My\u00e9lofibrose ","footnotes":""},"category":[11527,11531,11373,11389,11549],"tags":[12719,86103,86104,86105,86047,2284],"powerkit_post_featured":[],"class_list":["post-411814","post","type-post","status-publish","format-standard","has-post-thumbnail","category-etudes","category-formation-continue","category-hematologie","category-oncologie","category-rx-fr","tag-anemie","tag-inhibiteur-de-jak1-2","tag-inhibiteur-de-lacvr1","tag-inhibition-conventionnelle-des-jak","tag-momelotinib","tag-myelofibrose","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-02 18:25:42","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":411820,"slug":"nuove-opzioni-di-trattamento-per-i-pazienti-con-mielofibrosi-ad-alto-rischio-di-anemia","post_title":"Nuove opzioni di trattamento per i pazienti con mielofibrosi ad alto rischio di anemia?","href":"https:\/\/medizinonline.com\/it\/nuove-opzioni-di-trattamento-per-i-pazienti-con-mielofibrosi-ad-alto-rischio-di-anemia\/"},"pt_PT":{"locale":"pt_PT","id":411813,"slug":"novas-opcoes-de-tratamento-para-os-doentes-com-mielofibrose-que-apresentam-um-risco-elevado-de-anemia","post_title":"Novas op\u00e7\u00f5es de tratamento para os doentes com mielofibrose que apresentam um risco elevado de anemia?","href":"https:\/\/medizinonline.com\/pt-pt\/novas-opcoes-de-tratamento-para-os-doentes-com-mielofibrose-que-apresentam-um-risco-elevado-de-anemia\/"},"es_ES":{"locale":"es_ES","id":411819,"slug":"nuevas-opciones-de-tratamiento-para-los-pacientes-con-mielofibrosis-con-alto-riesgo-de-anemia","post_title":"\u00bfNuevas opciones de tratamiento para los pacientes con mielofibrosis con alto riesgo de anemia?","href":"https:\/\/medizinonline.com\/es\/nuevas-opciones-de-tratamiento-para-los-pacientes-con-mielofibrosis-con-alto-riesgo-de-anemia\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/411814","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=411814"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/411814\/revisions"}],"predecessor-version":[{"id":411818,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/411814\/revisions\/411818"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/411817"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=411814"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=411814"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=411814"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=411814"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}